Actavis is delighted to introduce to it's portfolio of products launched on day one of patent expiry. The patent expiry of Atorvastatin is set to create one of the biggest generic opportunities ever and allows pharmacists and the NHS to maximise the cost savings available by opting to dispense a generic.

Atorvastatin is indicated for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. Other products in Actavis’ portfolio within this therapy area include Fluvastatin and Simvastatin.

Michael Cann, Director Generics said: "Actavis is proud to give pharmacists and the NHS the opportunity to save costs by bringing Atorvastatin to market on the very first day of patent expiry.

"In the first four months of 2012 Actavis has brought twenty-two new product lines to market, eight of which have been available to pharmacists on day one of patent expiry.

"Delivering key products on day-one continues to be a focus for Actavis. We are dedicated to providing pharmacists with greater choice, wider availability and a reliable supply chain, which are important factors in the dispensing decision." 

Actavis is offering Atorvastatin in 10mg, 20mg, 40mg and 80mg packs of 28 tablets.

All products are available through major wholesalers or directly from the Actavis Telemarketing team on telephone: 0800 731 0370 or fax: 0800 731 0380.